NASDAQ:CDNA CareDx (CDNA) Stock Forecast, Price & News $6.62 -0.33 (-4.75%) (As of 10:08 AM ET) Add Compare Share Share Today's Range$6.62▼$6.9550-Day Range$6.86▼$11.2652-Week Range$6.22▼$20.71Volume103,374 shsAverage Volume1.02 million shsMarket Capitalization$358.61 millionP/E RatioN/ADividend YieldN/APrice Target$13.80 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability CareDx MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside98.6% Upside$13.80 Price TargetShort InterestHealthy7.20% of Shares Sold ShortDividend StrengthN/ASustainability-0.66Upright™ Environmental ScoreNews Sentiment0.58Based on 6 Articles This WeekInsider TradingSelling Shares$189,377 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.18) to ($2.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.08 out of 5 starsMedical Sector534th out of 965 stocksMedical Laboratories Industry14th out of 25 stocks 3.2 Analyst's Opinion Consensus RatingCareDx has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.80, CareDx has a forecasted upside of 98.6% from its current price of $6.95.Amount of Analyst CoverageCareDx has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.20% of the outstanding shares of CareDx have been sold short.Short Interest Ratio / Days to CoverCareDx has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in CareDx has recently decreased by 5.80%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCareDx does not currently pay a dividend.Dividend GrowthCareDx does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCareDx has received a 61.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "DNA sequencers", "Genomics analysis tools", and "Patient flow management systems" products. See details.Environmental SustainabilityThe Environmental Impact score for CareDx is -0.66. Previous Next 2.0 News and Social Media Coverage News SentimentCareDx has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for CareDx this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for CDNA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CareDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $189,377.00 in company stock.Percentage Held by InsidersOnly 4.20% of the stock of CareDx is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CareDx are expected to decrease in the coming year, from ($2.18) to ($2.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CareDx is -4.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CareDx is -4.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCareDx has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About CareDx (NASDAQ:CDNA) StockCareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Read More CDNA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDNA Stock News HeadlinesOctober 3, 2023 | finance.yahoo.comCareDx Issues Statement on Supreme Court Decision Regarding Stanford-Licensed PatentsOctober 3, 2023 | americanbankingnews.comCareDx, Inc (NASDAQ:CDNA) Insider Sells $19,472.38 in StockOctober 4, 2023 | Wall Street Fundamentals (Ad)Would Buffett Approve of This Growth Strategy?Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.October 2, 2023 | reuters.comUS Supreme Court rebuffs CareDx patent lawsuit over organ-rejection testsSeptember 27, 2023 | msn.comStephens & Co. Reiterates Caredx (CDNA) Equal-Weight RecommendationSeptember 27, 2023 | americanbankingnews.comCareDx's (CDNA) "Equal Weight" Rating Reaffirmed at StephensSeptember 19, 2023 | finance.yahoo.comCareDx To Present at the 2023 Cantor Global Healthcare ConferenceSeptember 14, 2023 | finance.yahoo.comCareDx Advances Global Transplant Patient Care at ESOT Congress 2023October 4, 2023 | Wall Street Fundamentals (Ad)Would Buffett Approve of This Growth Strategy?Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.August 31, 2023 | msn.comCaredx (CDNA) Price Target Increased by 8.00% to 11.02August 31, 2023 | finance.yahoo.comCareDx To Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 17, 2023 | finance.yahoo.comCareDx Hosts Second Annual MEET Digital Health User Conference to Showcase Latest Innovations to Enhance Transplant Patient CareAugust 15, 2023 | msn.comRaymond James Upgrades Caredx (CDNA)August 15, 2023 | finance.yahoo.comCareDx (NASDAQ:CDNA shareholders incur further losses as stock declines 13% this week, taking three-year losses to 73%August 11, 2023 | finance.yahoo.comCareDx Comments on Issuance of Proposed LCD for Molecular Testing for Solid Allograft RejectionAugust 10, 2023 | msn.comHC Wainwright & Co. Reiterates Caredx (CDNA) Neutral RecommendationAugust 9, 2023 | finance.yahoo.comCompared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key MetricsAugust 8, 2023 | finance.yahoo.comCareDx (CDNA) Reports Q2 Loss, Tops Revenue EstimatesAugust 8, 2023 | finance.yahoo.comCareDx Reports Second Quarter 2023 ResultsAugust 7, 2023 | finance.yahoo.comCareDx Announces District Court Judge Bars Natera from Falsely Advertising and Overstating the Scientific Performance of its Prospera Transplant TestAugust 4, 2023 | bizjournals.comScott Plank's organ transplant company MediGO sells to California companyAugust 3, 2023 | markets.businessinsider.comCraig-Hallum Reaffirms Their Hold Rating on CareDx (CDNA)August 3, 2023 | finance.yahoo.comCareDx to Report Second Quarter 2023 Financial ResultsAugust 2, 2023 | msn.comCareDx gains on Medicare coverage for HeartCare testAugust 2, 2023 | finance.yahoo.comCareDx’s HeartCare Multimodality Service Receives Medicare Coverage for Heart Transplant SurveillanceJuly 28, 2023 | seekingalpha.comCareDx: Regulatory Uncertainties Impacting RevenueJuly 25, 2023 | in.investing.comCareDx stock surges on the acquisition of MediGOSee More Headlines Receive CDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter. Email Address CDNA Company Calendar Last Earnings8/08/2023Today10/04/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CDNA CUSIPN/A CIK1217234 Webwww.caredxinc.com Phone(415) 287-2300Fax415-287-2450Employees727Year FoundedN/APrice Target and Rating Average Stock Price Forecast$13.80 High Stock Price Forecast$25.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+98.6%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,610,000.00 Net Margins-27.15% Pretax Margin-26.99% Return on Equity-19.84% Return on Assets-15.77% Debt Debt-to-Equity RatioN/A Current Ratio4.84 Quick Ratio4.59 Sales & Book Value Annual Sales$309.31 million Price / Sales1.22 Cash FlowN/A Price / Cash FlowN/A Book Value$8.05 per share Price / Book0.86Miscellaneous Outstanding Shares54,169,000Free Float51,894,000Market Cap$376.47 million OptionableOptionable Beta1.02 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Reginald Seeto M.D. (Age 51)MBBS, Pres, CEO & Director Comp: $954.71kMr. Abhishek Jain (Age 46)CFO & Principal Accounting Officer Comp: $425.58kMr. Abraham Ronai Esq. (Age 49)Chief Admin. & Legal Officer and Sec. Comp: $566.49kDr. Peter Maag Ph.D. (Age 56)Exec. Director Comp: $43.23kMs. Sasha King M.B.A. (Age 37)Exec. Officer Comp: $343.34kMr. Alexander L. Johnson (Age 48)Pres of Patient and Testing Services Comp: $547.43kMs. Marica Grskovic Ph.D.Chief Operating OfficerMr. Ian CooneyVP of Investor RelationsDr. Mickey Y. Kim M.D.Sr. VP of Corp. Devel. & Head of Global ProductMr. Jarrod BorkatSr. VP and Head of Marketing & Portfolio OperationsMore ExecutivesKey CompetitorsCastle BiosciencesNASDAQ:CSTLCelcuityNASDAQ:CELCInvitaeNYSE:NVTAHH&L AcquisitionNYSE:HHLAViridian TherapeuticsNASDAQ:VRDNView All CompetitorsInsiders & InstitutionsReginald SeetoSold 2,818 sharesTotal: $19,472.38 ($6.91/share)Reginald SeetoSold 2,819 sharesTotal: $26,752.31 ($9.49/share)California State Teachers Retirement SystemSold 1,434 shares on 8/21/2023Ownership: 0.119%Osaic Holdings Inc.Sold 3,158 shares on 8/21/2023Ownership: 0.034%Alliancebernstein L.P.Bought 8,030 shares on 8/15/2023Ownership: 0.131%View All Insider TransactionsView All Institutional Transactions CDNA Stock - Frequently Asked Questions Should I buy or sell CareDx stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last twelve months. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CDNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CDNA, but not buy additional shares or sell existing shares. View CDNA analyst ratings or view top-rated stocks. What is CareDx's stock price forecast for 2023? 6 brokerages have issued 1-year target prices for CareDx's stock. Their CDNA share price forecasts range from $9.00 to $25.00. On average, they expect the company's stock price to reach $13.80 in the next twelve months. This suggests a possible upside of 98.6% from the stock's current price. View analysts price targets for CDNA or view top-rated stocks among Wall Street analysts. How have CDNA shares performed in 2023? CareDx's stock was trading at $11.41 at the start of the year. Since then, CDNA stock has decreased by 39.1% and is now trading at $6.95. View the best growth stocks for 2023 here. Are investors shorting CareDx? CareDx saw a decline in short interest during the month of September. As of September 15th, there was short interest totaling 3,900,000 shares, a decline of 5.8% from the August 31st total of 4,140,000 shares. Based on an average daily trading volume, of 835,900 shares, the days-to-cover ratio is presently 4.7 days. View CareDx's Short Interest. When is CareDx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our CDNA earnings forecast. How were CareDx's earnings last quarter? CareDx, Inc (NASDAQ:CDNA) announced its earnings results on Tuesday, August, 8th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.10. The business earned $70.30 million during the quarter, compared to the consensus estimate of $56.40 million. CareDx had a negative trailing twelve-month return on equity of 19.84% and a negative net margin of 27.15%. What ETFs hold CareDx's stock? ETFs with the largest weight of CareDx (NASDAQ:CDNA) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Jacob Forward ETF (JFWD), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and Global X Genomics & Biotechnology ETF (GNOM).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG). What guidance has CareDx issued on next quarter's earnings? CareDx issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $240.00 million-$260.00 million, compared to the consensus revenue estimate of $261.94 million. What other stocks do shareholders of CareDx own? Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Block (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Enphase Energy (ENPH), Johnson & Johnson (JNJ), Activision Blizzard (ATVI) and Alibaba Group (BABA). What is CareDx's stock symbol? CareDx trades on the NASDAQ under the ticker symbol "CDNA." How do I buy shares of CareDx? Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is CareDx's stock price today? One share of CDNA stock can currently be purchased for approximately $6.95. How much money does CareDx make? CareDx (NASDAQ:CDNA) has a market capitalization of $376.47 million and generates $309.31 million in revenue each year. The company earns $-76,610,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis. How many employees does CareDx have? The company employs 727 workers across the globe. How can I contact CareDx? CareDx's mailing address is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.caredxinc.com. The company can be reached via phone at (415) 287-2300, via email at caroline.corner@westwicke.com, or via fax at 415-287-2450. This page (NASDAQ:CDNA) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CareDx, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.